# BPC-157: Research Overview — Prime Peptide Labs > A literature summary of BPC-157 (Body Protection Compound 157), a stable gastric pentadecapeptide: angiogenesis mechanism, rodent healing studies, pharmacokinetics, and regulatory status. Body Protection Compound 157 — a stable gastric pentadecapeptide whose repair effects in animals track most consistently with the growth of new blood vessels. ## The short version BPC-157 stands for **Body Protection Compound 157**. It is a synthetic peptide fifteen amino acids long, copied from part of a protective protein found in human stomach juice. In animal studies — overwhelmingly in rats — it appears to speed up healing in many tissue types: the gut lining, tendons, muscle, and more [17][16]. The most consistent explanation researchers give is that it helps the body grow new blood vessels into an injury, delivering the oxygen and nutrients repair needs [16]. Here is the honest part. Almost all of this evidence is in animals. As of 2025 reviews, only three small human pilot studies exist, and there are no large, rigorous human trials [14]. BPC-157 is not an approved drug anywhere and is banned in sport. Common online claims about weight loss or muscle building are not supported by the published science [14]. This page summarizes what was studied; it is not advice and lists no human dose. ## What it is BPC-157 is a *stable gastric pentadecapeptide* — "pentadecapeptide" means a fifteen-amino-acid chain, and "stable gastric" refers to the fact that the sequence is drawn from a cytoprotective protein in gastric juice and resists breakdown in stomach acid. Its sequence is `Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val`, and it is catalogued under research designations including PL 14736, PLD-116, and PL-10. It is a synthetic research peptide — not extracted from a natural source, and not an approved drug anywhere. ## How it works The best-characterized mechanism is *angiogenesis* — the formation of new blood vessels. In a 2017 study spanning a chick-membrane model, rat hindlimb ischemia, and human endothelial cells, BPC-157 increased expression of the vessel-growth receptor VEGFR2 and promoted its internalization, switching on the downstream VEGFR2-Akt-eNOS pathway; blocking that internalization blocked the effect [16]. In plain terms: it appears to make blood-vessel-lining cells more responsive to the body's own "grow new vessels" signal and accelerated blood-flow recovery in a blocked-circulation muscle model. Additional reported pathways include modulation of the nitric-oxide system, sensitization of the growth-hormone receptor in tendon fibroblasts, FAK-paxillin cell-migration signaling, and brain-gut axis interactions [16]. The picture is a peptide that nudges several repair-related signals at once rather than targeting a single receptor. ## What the research shows *Foundational cytoprotection.* The compound's name traces to its gut origins. In Wistar rats, BPC-157 reduced gastric-ulcer area and accelerated ulcer healing, with intramuscular delivery outperforming intragastric, and ulcer-formation inhibition ratios of roughly 46-66% at higher doses [17]. *Angiogenesis mechanism.* BPC-157 up-regulated VEGFR2 expression and promoted VEGFR2 internalization with downstream VEGFR2-Akt-eNOS activation, increasing vessel density in vivo and in vitro and accelerating blood-flow recovery in ischemic muscle [16]. *Pharmacokinetics.* The first formal PK/ADME characterization, in rats and beagle dogs, found linear pharmacokinetics, a very short elimination half-life under 30 minutes, modest intramuscular bioavailability (~14-19% in rats, ~45-51% in dogs), and rapid breakdown into small peptide fragments that re-enter normal amino-acid metabolism [15]. A short half-life means the intact peptide does not linger in the bloodstream. *Human evidence.* It is genuinely small. A 2025 first-in-human intravenous safety pilot gave BPC-157 up to 20 mg to two healthy adults; it was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers — but the sample size was two people, and it was a safety pilot, not an efficacy study [13]. A 2025 narrative review concludes that only three pilot studies have examined BPC-157 in humans, that rigorous large-scale trials are lacking, and that the peptide should be treated as investigational [14]. ## Reported effects, cautions & safety The safety picture inside the tiny human dataset and the animal work is reassuring as far as it goes — but "as far as it goes" is the operative phrase: the absence of long-term, large-sample human safety data means the real-world safety profile is genuinely unknown [14]. Several cautions follow directly from the literature: - *Evidence is overwhelmingly preclinical.* Most of what is reported comes from rodents, and a large share of the foundational work originates from a single research group, which newer authors explicitly flag as raising independent-replication questions [14]. - *Unregulated supply.* BPC-157 is not an approved drug anywhere and is widely distributed through non-regulated channels, so product identity, purity, and dose are unverified outside formal studies. - *Banned in sport.* It is prohibited at all times by the World Anti-Doping Agency under the S0 (non-approved substances) category — a direct concern for competitive athletes [8]. - *Overstated claims.* Common online claims such as weight loss, muscle building, or raising testosterone are not supported by the published evidence and should be treated skeptically [14]. ## Where it fits in recovery research Among the three peptides on this desk, BPC-157 has the broadest animal record — spanning tendon, gut, muscle, and nerve repair — but breadth is not the same as depth. Its human file remains three small pilots, and a large share of the foundational evidence comes from a single group [14]. Read alongside [GHK-Cu](/ghk-cu), which carries the strongest human topical data, and [TB-500](/tb-500), whose evidence largely belongs to the parent protein, BPC-157 illustrates the central tension of this whole field: a coherent, decades-deep preclinical signal that has barely crossed into controlled human work. See the [comparison page](/compare) for how it lines up against the others. ![BPC-157 peptide chain and angiogenic tissue-repair lattice in cold azure graphite](/images/bpc-157.webp) --- A plain-language reading desk for recovery-peptide research — citations on every claim, no products, no prescriptions.